Samsung Bioepis gets positive CHMP opinion on Remicade biosimilar

Incheon-based Samsung Bioepis won a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for its Remicade biosimilar, paving the way for more competition in reimbursed markets in Europe.

The inflammatory disease therapy Flixabi, a biosimilar of infliximab, was recommended for approval after meeting EMA quality, efficacy and safety requirements for biosimilars, the South Korean company formed as part of a joint venture with Biogen ($BIIB) said in a press release.

SB2, the in-house name of the product, is one of 6 biosimilar candidates either approved in regulated markets such as Enbrel (etanercept) or in development on the regulatory pathway that include versions of Remicade, Lantus (insulin glargine), Humira (adalimumab), Herceptin (trastuzumab) and Avastin (bevacizumab)--with another 7 molecules at early stages.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

"The CHMP's positive opinion on Flixabi brings us a step closer to broadening affordable, high-quality treatment options for autoimmune patients across Europe," Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in a statement.

Samsung Bioepis CEO Christopher Ko

"We will continue to leverage our strengths in product development and quality assurance, so that we can increase patient access to a wider choice of life-enhancing medications."

For Remicade, formal marketing approval would put it head-to-head with a biosimilar version from Hospira, now owned by Pfizer ($PFE), and its South Korea-based partner Celltrion which sell under the brand names Inflectra and Remsima, respectively.

Sales of Remicade, partnered by Johnson & Johnson ($JNJ) and Merck ($MRK), have already been hit in Europe and elsewhere by a recent report suggesting real-world data on the use of Hospira/Celltrion's biosimilar found it safe and effective--and cheaper.

In February, the U.S. FDA's arthritis panel approved Celltrion's version in all indications including psoriatic arthritis, Crohn's disease, ulcerative colitis and psoriasis.

- here's the release

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.